Dr. Roboz on the QuANTUM-R Trial in AML

Video

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus salvage chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

Patients who have relapsed or refractory FLT3-mutated AML have a poor prognosis, a high frequency of relapse, and poor response to salvage therapy.

This patient population has a high unmet need for appropriate therapy, and quizartinib, a second-generation FLT3 inhibitor, was investigated as a proposed treatment in the QuANTUM-R study, which is a randomized, controlled, phase III trial at 152 centers that compared the proposed agent with chemotherapy in patients with FLT3-mutated AML.

Roboz explains that the completed phase III study showed that treatment with quizartinib had a survival benefit versus salvage chemotherapy. Moreover, the agent also demonstrated an acceptable safety profile.

<<< 2019 European Hematology Association Congress

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Guenther Koehne, MD, PhD
Lori A. Leslie, MD, an expert on lymphoma
Lori A. Leslie, MD, an expert on lymphoma
A panel of 4 experts on MDS
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania